Respiratory diseases are becoming increasingly important (allergies, environmentally induced asthma, smoking, etc.). Pulmonary products are one of the main focuses of the Chiesi Group’s development and marketing activities. A highlight in this area was the patenting of respiratory sprays based on a freon-free (Modulite®) technology. The Torrex Chiesi Group’s own product portfolio is being expanded through the addition of Prolastin®, an important drug for a rare genetically-related disorder (alpha1-antitrypsin-deficiency).
go to Therapeutic Areas